KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Twist Bioscience (TWST) Shares Outstanding (Weighted Average) (2017 - 2025)

Twist Bioscience (TWST) has disclosed Shares Outstanding (Weighted Average) for 9 consecutive years, with $61.1 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 3.24% to $61.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61.1 million through Dec 2025, up 3.24% year-over-year, with the annual reading at $59.8 million for FY2025, 3.09% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $61.1 million at Twist Bioscience, up from $59.8 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $61.1 million in Q4 2025, with the low at $47.3 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $55.7 million, with a median of $57.0 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) grew 27.38% in 2021, then grew 1.34% in 2023.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $49.9 million in 2021, then rose by 13.09% to $56.4 million in 2022, then increased by 1.87% to $57.5 million in 2023, then grew by 2.9% to $59.2 million in 2024, then grew by 3.24% to $61.1 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $61.1 million, $59.8 million, and $60.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.